MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
6.83
+0.39
+6.06%
After Hours: 6.51 -0.32 -4.63% 18:45 12/31 EST
OPEN
6.90
PREV CLOSE
6.44
HIGH
7.33
LOW
6.50
VOLUME
60.38K
TURNOVER
--
52 WEEK HIGH
468.44
52 WEEK LOW
6.08
MARKET CAP
6.26M
P/E (TTM)
-0.0193
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAZ last week (1222-1226)?
Weekly Report · 12/29/2025 09:22
TransCode Therapeutics Files Amended 8-K on ABCJ Acquisition
Reuters · 12/23/2025 21:16
Transcode Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Elizabeth Czerepak
Reuters · 12/22/2025 21:40
Transcode Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Jack E. Stover
Reuters · 12/22/2025 21:39
TransCode Therapeutics Strengthens Board with Veteran Financial Expert
TipRanks · 12/22/2025 13:28
TransCode Therapeutics Appoints Jack E. Stover to Board of Directors
Reuters · 12/22/2025 13:04
TRANSCODE THERAPEUTICS EXPANDS LEADERSHIP WITH APPOINTMENT OF JACK E. STOVER TO BOARD OF DIRECTORS
Reuters · 12/22/2025 13:01
Press Release: TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
Dow Jones · 12/22/2025 13:01
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.